CASI Pharmaceuticals Files March 2025 Report
Ticker: CASIF · Form: 6-K · Filed: Mar 31, 2025 · CIK: 1962738
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
CASI Pharma dropped a March update (6-K) on 3/31, including a press release. Nothing earth-shattering, just routine reporting.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on March 31, 2025, reporting on activities for the month of March 2025. The filing includes a press release dated March 31, 2025, as Exhibit 99.1. The company previously operated under the name CASI Pharmaceuticals Holdings, Inc. before changing its name on January 18, 2023.
Why It Matters
This filing provides an update on CASI Pharmaceuticals' activities and disclosures for March 2025, which is important for investors to stay informed about the company's ongoing operations and any significant announcements.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain new financial results or significant operational changes.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Registrant
- CASI Pharmaceuticals Holdings, Inc. (company) — Former company name
- March 31, 2025 (date) — Filing date and press release date
- January 18, 2023 (date) — Date of name change
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed by CASI Pharmaceuticals, Inc. pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of March 2025.
What is included as an exhibit in this filing?
Exhibit 99.1, a Press Release of CASI Pharmaceuticals, Inc. dated March 31, 2025, is included in this filing.
When did CASI Pharmaceuticals, Inc. change its name?
The company's name was changed from CASI Pharmaceuticals Holdings, Inc. on January 18, 2023.
What is the principal executive office address of CASI Pharmaceuticals, Inc.?
The principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Does CASI Pharmaceuticals file annual reports under Form 20-F or Form 40-F?
CASI Pharmaceuticals indicates it files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 31, 2025 regarding CASI Pharmaceuticals, Inc. (CASIF).